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A B S T R A C T
Background: Pressure ulcers are serious, avoidable, costly and common adverse outcomes of healthcare.
Objectives: To evaluate the cost-effectiveness of a patient-centred pressure ulcer prevention care bundle com-
pared to standard care.
Design: Cost-effectiveness and cost-benefit analyses of pressure ulcer prevention performed from the health
system perspective using data collected alongside a cluster-randomised trial.
Settings: Eight tertiary hospitals in Australia.
Participants: Adult patients receiving either a patient-centred pressure ulcer prevention care bundle (n = 799) or
standard care (n = 799).
Methods: Direct costs related to the intervention and preventative strategies were collected from trial data and
supplemented by micro-costing data on patient turning and skin care from a 4-week substudy (n = 317). The
time horizon for the economic evaluation matched the trial duration, with the endpoint being diagnosis of a new
pressure ulcer, hospital discharge/transfer or 28 days; whichever occurred first. For the cost-effectiveness ana-
lysis, the primary outcome was the incremental costs of prevention per additional hospital acquired pressure
ulcer case avoided, estimated using a two-stage cluster-adjusted non-parametric bootstrap method. The cost-
benefit analysis estimated net monetary benefit, which considered both the costs of prevention and any dif-
ference in length of stay. All costs are reported in AU$(2015).
Results: The care bundle cost AU$144.91 (95%CI: $74.96 to $246.08) more per patient than standard care. The
largest contributors to cost were clinical nurse time for repositioning and skin inspection. In the cost-effec-
tiveness analysis, the care bundle was estimated to cost an additional $3296 (95%CI: dominant to $144,525) per
pressure ulcer avoided. This estimate is highly uncertain. Length of stay was unexpectedly higher in the care
bundle group. In a cost-benefit analysis which considered length of stay, the net monetary benefit for the care
bundle was estimated to be−$2320 (95%CI−$3900,−$1175) per patient, suggesting the care bundle was not
a cost-effective use of resources.
Conclusions: A pressure ulcer prevention care bundle consisting of multicomponent nurse training and patient
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education may promote best practice nursing care but may not be cost-effective in preventing hospital acquired
pressure ulcer.
What is already known about the topic?
• Pressures ulcers are an avoidable adverse event that result in poor
patient outcomes and escalate healthcare costs.
• Few studies have explored the cost-effectiveness of a patient-centred
care bundle as a pressure ulcer prevention strategy.
What this paper adds
• This economic evaluation alongside a large cluster-randomised trial
suggests a care bundle is unlikely to be cost-effective in preventing
pressure ulcers but these findings are inconclusive.
• The largest contributors to prevention costs related to clinical nurse
time for repositioning and skin inspection, which are components of
best nursing practice.
1. Introduction
Pressure ulcers (PUs) are amongst the most common iatrogenic
events associated with healthcare, and also one of the most costly. They
have substantial impact on patients in terms of reduced health-related
quality of life (HRQOL) and extended length of hospital stay (LOS)
(Sebba Tosta de Souza et al., 2015; Hengstermann et al., 2007; Vetrano
et al., 2014; Gorecki et al., 2009). In Australia, PUs are associated with
a median increase of 4.3 days in LOS for acute admissions (Graves et al.,
2005) In the USA, the mean LOS in patients who developed Stage II −
IV PU during admission was significantly greater (20.9 days) than pa-
tients who did not develop PU (12.7 days) after adjusting for other
predictors of LOS (Allman et al., 1999). This increase in LOS results in
increased healthcare costs, ranking PUs as the fifth most costly com-
plication in public hospitals in Australia (Jackson, 2011). The total cost
attributed to PU in Australian public hospitals is estimated to exceed
AU$1.8 billion per annum (approximately US$1.3 billion; AU$ ∼US
$0.74 at June 2016) or 1.9% of public hospital expenditure (Nguyen
et al., 2015). The majority of this cost is attributed to PU treatment (AU
$983 million) with the remainder being the opportunity cost associated
with lost bed days (AU$820 million or 525,000 bed days) (Nguyen
et al., 2015). However, the cost of treating PU varies widely by Stage,
with the mean treatment cost per patient ranging from AU$2747 for
Stage I to $22,467 for Stage IV; whilst, the majority of additional bed
days are attributed to Stage II to IV PU (Nguyen et al., 2015).
PUs are considered preventable, and as such are at the forefront of
hospital safety agendas (Australian Commission on Safety and Quality
in Health Care, 2011; Rosenthal, 2007; Power et al., 2012). Pressure
ulcer prevention (PUP) has the potential for substantial improvements
in HRQOL and to save the health system millions of dollars. Although
the cost of PUP strategies per individual may be low (Demarre et al.,
2015a, 2015b), the need for common application of these suggests an
imperative to find the most cost-effective strategy. Few trials of PUP
have included economic evaluations (Gillespie et al., 2014; Reddy et al.,
2006). Thus, the cost-effectiveness of PUP remains poorly understood.
Pragmatic care bundles consisting of multi-faceted structured in-
terventions have the potential to improve patient safety and quality of
care in care settings through for example reduced falls and infections
(Chaboyer et al., 2015; van Gaal et al., 2011; Boyd et al., 2011). Such
interventions could have a beneficial impact on patients, their families
and the health care system, through improved HRQOL and reduced
hospital LOS. Patient-centred care bundles are now recognised as an
important strategy to explore further in the quality and safety agenda
(Chaboyer et al., 2015). The patient is arguably an underutilised
resource in care settings, representing an undervalued contribution to
the health system.
PUP is one area high on the health quality and safety agenda where
the potential economic benefits of a patient-centred care bundle have
not been previously assessed. We performed a cost-effectiveness ana-
lysis (CEA) and cost-benefit analysis (CBA) using data from a pragmatic
cluster-randomised trial (c-RT); the INTroducing A Care bundle To
prevent pressure ulcer in at-risk patients (INTACT) trial (Chaboyer
et al., 2015, 2016), to compare the direct healthcare costs and effects of
a pressure ulcer prevention care bundle (PUPCB), relative to standard
care.
2. Materials and methods
2.1. Study design
The INTACT trial recruited 1600 adult medical and surgical patients
at risk of PU across eight tertiary hospital sites in Australia. The trial
methodology and clinical findings have been detailed elsewhere
(Chaboyer et al., 2015, 2016). Sites were stratified by PU incidence rate
and randomised for patients to receive either (i) a multicomponent
PUPCB program consisting of information and education resources
targeted to patients (DVD, poster, brochure, face-to-face education) and
nurse training package; or (ii) standard care which was aligned with
regional guidelines. The primary outcome was incidence of hospital
acquired pressure ulcer (HAPU) of any stage (Haesler, 2014). Hospital
length of stay (LOS) was recorded for all participants and was used to
estimate time in the study, with the study endpoint and therefore time
horizon for economic evalution being either diagnosis of a new HAPU,
day of discharge or transfer to another hospital or critical care, or
28 days; whichever occurred first. The trial reported a HAPU incidence
rate of 14·4 per 1000 person-days across the whole sample; 9·6 per 1000
person-days in the PUPCB group and 20·1 per 1000 person-days in the
standard care group (incidence rate ratio 0·48; 95% CI: 0·33, 0·69;
p < 0·0001) (Chaboyer et al., 2016). However, this reduction in risk
was not statistically significant after adjusting for clustering and pre-
specified covariates (adjusted hazard ratio 0.58, 95% CI: 0.25, 1.33,
p = 0.198).
The economic evaluation was undertaken from the health system
perspective using data collected alongside the trial, and evaluated the
costs and benefits of PUP expressed as both the cost-effectiveness (the
incremental cost of preventing an additional case of HAPU or of an
additional day free of HAPU) and the cost-benefit (the net monetary
benefits associated with the PUPCB). As the duration of the trial was
less than one year, discounting was not applied to costs or benefits.
2.2. Cost and resource use data
Data on the cost of administering the PUPCB, including production
of brochures, posters and DVD materials and nurse time to deliver the
intervention to each patient, were collected for all trial participants.To
supplement this, micro-costing data were collected during a 4-week
observational period for each site (between September 2014 and
February 2015) on a subsample of trial participants, targeting 40 from
each site (n = 320 total subsample). This sample size reflected 20% of
the trial cohort, and was considered sufficient to indicate the mean and
distribution of resource use in the cohort. Detailed data on resource use
related to PUP were collected by Research Assistants during usual
working hours. The data were collected by direct observation of the
subsample over an 8-h period, asking participants about events in the
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other 16 h of a 24-h period, and auditing medical records. Observation
occurred for each participant for a single consecutive period of eight
daytime hours sometime between study days 2 and 6. Data from the
subsample were used to determine the number of repositioning epi-
sodes per participant over the 8-h observation period, number of clin-
ical staff required for each repositioning, and the nurse time required
per turn. These data were combined to give the mean nurse time re-
quired per patient in the 8-h period, and then extrapolated to a 24-h
period using patient self-report data on the number of turns for the
other 16 h in the day of observation. The mean nurse turning time and
mean number of skin inspections for 24 h for each cluster were extra-
polated across all participants for each day in the study. Other resource
use related to PUP such as the rate of patients consulting a dietitian was
also recorded for the subsample and extrapolated to all trial partici-
pants.
Mean values for each hospital cluster from the subsample were
applied to each trial participant dependent on their cluster. Thus,
subsample data were used alongside PUPCB intervention and duration
in the trial to estimate the total resource use and direct healthcare cost
related to PUP per participant over the entire study period. Direct costs
(inflated to AU$ 2015 using the Consumer Price Index for Health
December 2015 ABS, 2015 where applicable) were allocated to each
resource unit using standard costing sources. Table 1 summarises the
resource utilisation data recorded in the main and subsample and the
unit costs assigned.
2.3. Cost-effectiveness analysis
For the cost-effectiveness analysis, the primary measure of effec-
tiveness was cases of HAPU prevented; this was aligned with the pri-
mary trial outcome (HAPU incidence) and was the outcome specified
for the cost-effectiveness analysis in the trial protocol (Chaboyer et al.,
2015). In addition, to account for any possible delay in developing a PU
that might be associated with the intervention, a secondary analysis
also used days remaining free of HAPU as an outcome. This was mea-
sured as the days in the study (i.e. from study enrolment until end
point).
To provide insight into whether the PUPCB was cost-effective, the
following values were assumed as willingness to pay threhsolds for an
improvement in outcome, from the perspective of the Australian health
system. These values were based on an Australian study which esti-
mated the costs of treating a HAPU by stage including the opportunity
costs associated with associated LOS (Nguyen et al., 2015), converted to
2015 AU$:
(i) AU$3060 or AU$11,529.14 per additional HAPU Stage I or II
Table 1
Summary of resource data collection and costing methods.
Resource measured Unit cost (AU$) Source for unit cost Resource data collection, costing approach & assumptions
I. PUPCB Intervention
Materials
Photo shoot ×2 528 Commercial provider Averaged a
Poster design 440 Commercial provider Averaged a
Brochure design 690 Commercial provider Averaged a
DVD speaker 50 Commercial provider Averaged a
DVD production 4950 Commercial provider Averaged a
DVD production (edit) 2600 Commercial provider Averaged a
Art work 360 Commercial provider Averaged a
Poster printing ×1000 390 Commercial provider Averaged a
Brochure printing ×1000 390 Commercial provider Averaged a
Time for nurses to receive training in PUPCB
(nurse number trained; training duration
mins)
45.34/hour Hospital casual rate for Nurse
Grade 5 level 4 (mid-range)
Averaged a.
Hospital 1: (50;120)
Hospital 2: (66;140)
Hospital 3: (63;120)
Hospital 4: (38;80)
Time to deliver PUPCB materials to patients 45.34/hour Hospital casual rate for Nurse
Grade 5 level 4 (mid-range)
Recorded for all trial participants
II. PUP strategies − nurse time
Repositioning 45.34/hour Hospital casual rate for Nurse
Grade 5 level 4 (mid-range)
Subsample: number of nurses per turn, turns per patient and time per turn
observed over 8-h, extrapolated to trial cohort.b,c
Skin inspection 45.34/hour Hospital casual rate for Nurse
Grade 5 level 4 (mid-range)
Subsample: number of skin inspections per patient observed over 8-h,
extrapolated to trial cohort.b,c Assumes 5 min nurse time per skin
inspection.
III. Other PU prevention
Bed complements Per product: Hospital cost centre Recorded for all trial participants. Cost of product annuitized, d then
applied to number of days product was used, which was recorded for all
trial participants.
(a) Wedge (a) 110 (0.33/day)
(b) Elbow/heel bootie (b) 55 (0.21/day)
(c) Chair cushion (c) 45.54 (0.13/
day)
(d) Air mattress/overlay mattress/special
bed
(d) 10,000 (6.86/
day)
Nutrition Subsample: dietitian consults per patient observed over 24-h using patient
self-report, extrapolated to trial cohort.c Consult assumed to be 30 min.(a) Dietitian consult (a) 48.78 per hour Hospital casual rate for
Dietitian Grade HP3.4 (mid-
range).
(b) PUP specific nutritional care plan (high
protein diet)
(b) 3 per day for
high protein diet
Hospital cost centre
All participants: Number of days under care plan recorded
Skin care 2.40 per tube
(100 g)
Pharmacy price of basic skin
moisturiser (sorbolene)
One tube for each participant using skin cream, regardless of duration of
use.
a Averaged across all participants receiving PUPCB.
b Extrapolated to 24-h using patient self-report for the non-observed 16-h (to maximum of 9 reposition episodes in 24 h).
c Cluster-dependent mean in subsample extrapolated to trial, adjusted for number of days in study.
d Annuitised, assuming a 1 year (a,b,c) or 5 year (d) life, no residual value, 5% discount rate.
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prevented respectively.
(ii) AU$109.31 or AU$110.67 per additional day free of HAPU Stage I
or II respectively.
The willingness-to-pay for an outcome was estimated by weighting
the thresholds above by the probability of PU stage observed in the
clinical study (Chaboyer et al., 2016). In the clinical study, the standard
care group experienced 35 more HAPU cases than the PUPCB group, of
which 32 cases were stage I and 3 cases were stage II. After this
weighting was applied, the willingness-to-pay thresholds used were
A$3786.43 per HAPU case avoided and A$110.76 per additional day
free of HAPU in 2015 dollars.
2.4. Cost-benefit analysis
As an alternative approach to assessing whether the PUPCB was of
acceptable cost-effectiveness, a cost-benefit analysis was undertaken
using hospital LOS as the outcome measure to reflect the benefits as-
sociated with preventing HAPU. The net monetary benefit (NMB) as-
sociated with PUPCB compared to standard care was estimated as
[(incremental benefit x threshold)− incremental costs]. The threshold
(willingness to pay) for a one day reduction in LOS was assumed to be
the cost allocated to an additional long stay outlier for a patient with an
Australian–Refined Diagnosis Related Group (AR-DRG) code J60-B
(skin ulcer without catastrophic complications), which equates to AU
$813.64 per day (2014/5) (Independent Hospital Pricing Authority,
2014). Thus, a NMB of zero would suggest a break-even point (as-
suming this willingness to pay threshold), a positive NMB would favour
the PUPCB, and a negative NMB would favour standard care.
2.5. Evaluation of differences in costs and benefits
Cluster-adjusted T-tests were used to compare costs for distinct re-
source items between groups. A two-stage cluster-adjusted non-para-
metric bootstrapping technique was employed (using 10,000 replica-
tions with replacement) to compare mean difference in the costs of
prevention between groups, and to estimate the incremental cost-ef-
fectiveness ratios, along with 95% percentile method confidence in-
tervals (CIs) around the point estimates (Ng et al., 2013). STATA
(Version 13, StataCorp, USA) was employed for data analysis.
2.6. Sensitivity analysis
Hospital LOS may reflect the patient’s underlying condition and not
any benefits of PUP, particularly given most PUs observed in the study
were Stage I. Therefore, a sensitivity analysis was undertaken excluding
long stay outlier participants whose LOS was above or below the mean
plus two standard deviations for their intervention group. This assesses
the robustness of the findings, assuming that LOS for ‘more complex'
patients is mainly based on their general medical condition and not
only the presence of PUs.
3. Results
3.1. Study participants
The main trial enrolled 1600 patients and analysed 1598 (799 to
each arm). The characteristics of trial participants have been reported
previously (Chaboyer et al., 2016); participants were a median of 71
years old, 52% were female, and 10% had an existing PU at baseline.
The sub-study included 317 participants, with between 29 and 46 pa-
tients recruited from each site. The subsample had similar character-
istics to the overall trial sample with the exception that surgical ad-
mission patients were over-represented in the subsample (70%)
compared to the full sample (34%).
3.2. HAPU related costs
Table 2 provides a comparison of the resource use and cost per
participant, by individual resource type. The largest contributor to
prevention costs related to clinical nurse time to reposition the patients
or to inspect their skin. The intervention costs also contributed sub-
stantially for the PUPCB group. The other PUP strategy products and
nutrition contributed relatively little to the costs. There was a sig-
nificant difference between groups for the costs associated with skin
inspection, which were a mean of $44.27 more costly for PUPCB than
for standard care (p = 0.014).
3.3. Differences in costs of prevention and outcomes
Table 3 shows the difference in prevention costs and outcomes.
PUPCB is estimated to cost $144.91 (95%CI $74.96 to $246.08) more
per patient than standard care. With respect to outcomes, the cluster-
adjusted bootstrap did not show a significant difference in the prob-
ability of avoiding a PU. However, PUPCB was associated with an
Table 2
HAPU related prevention costs by group.
PUPCB (per patient) Standard care (per patient) P valuea
units Cost ($) Mean ± SD units Cost ($) Mean ±SD
(I) PUPCB Intervention
Materials NA 13.01 NA NA NA
Training Nurses 0.54 h 24.44 ± 8.7 NA NA
Deliver to Patients 0.16 h 7.19 ± 4.1 NA NA
(II) PUP strategies: nurse time (per patient extrapolated across LOS)
Repositioning episodes 2.44 h 110.69 ± 121.04 1.28 h $ 58.07 ± 41.67 0.343
Skin Inspection 1.60 h 72.47 ± 58.97 0.62 h $ 28.20 ± 24.98 *0.014
(III) PUP strategies: Other PU prevention
Bed Complements 7.57 ± 21.14 6.50 ± 15.83 0.711
(a) Wedges 0.37 days 0.12 ± 0.37 0.26 days 0.08 ± 0.35 0.622
(b) Elbow/heel bootie 0.15 days 0.03 ± 0.12 0.10 days 0.02 ± 0.11 0.630
(c) Chair cushion 0.43 days 0.06 ± 0.21 0.24 days 0.03 ± 0.13 0.397
(d) Air mattress 1.07 days 7.37 ± 20.99 0.93 days 6.36 ± 15.63 0.727
Nutrition 6.39 ± 7.56 5.06 ± 5.92 0.674
(a) Dietitian consulted 24/799 3.63 ± 2.78 21/799 3.12 ± 2.71 0.825
(b) Nutrition care plan 0.92 days 2.75 ± 6.89 0.65 days 1.94 ± 4.49 0.406
Skincare (creams) 2.62 days 1.60 ± 1.13 1.47 days 1.16 ± 1.20 0.320
NA Not applicable; * p≤ 0.05.
a P-value is significance for cluster-adjusted T-test between costs.
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increased number of days free of PU per participant (mean difference
1.12 days per patient, 95%CI 0.34–1.82).
3.4. Cost-effectiveness of the PUPCB
Table 4 presents the incremental cost-effectiveness ratio (ICER) es-
timates for PUPCB compared to standard care. PUPCB is estimated to
cost an additional $3296 per PU case avoided (95%CI dominant to
$144,525) or $151 per additional day free of PU (95%CI $57 to $313)
per patient. The point estimate for PU case avoided suggests that
PUPCB may be cost-effective when making reasonable assumptions
around the willingness to pay thresholds for a PU prevented ($3786).
However, conversely the point estimate for additional day free of PU
suggests it may not be cost-effective given the assumed willingness to
pay threshold ($110 per additional day free of PU). Moreover, the es-
timate of cost-effectiveness is highly uncertain, as shown by the very
wide confidence intervals and high proportion of points either side of
the assumed willingness to pay threshold in the cost-effectiveness plane
(Fig. 1).
Fig. 2 shows the cost-effectiveness acceptability curve for PUPCB
compared to standard care. There is a 55.01% likelihood that the
PUPCB intervention is cost-effective at an assumed willingness-to-pay
threshold of A$3786 per HAPU case prevented. PUPCB is more likely to
be cost-effective than standard care at a willingness to pay threshold of
$3360 per PU avoided or above.
3.5. Length of stay (LOS) and cost-benefit of the PUPCB
Whilst the median LOS was 6 days in the PUPCB group compared to
5 days in standard care (cluster-adjusted non-parametric test p = 0.06)
(Chaboyer et al., 2016), the mean LOS was 2.67 (95%CI 1.22 to 4.70)
longer for PUPCB (10.46 days) than for standard care (7.78 days)
(Table 5). This translates to an incremental benefit of $2175 (95%CI
$991 to $3824) driven by a lower LOS favouring standard care. After
considering prevention costs, the NMB for PUPCB compared to standard
care is −$2,319.51 (95%CI −$3,900.34, −$1,174.84), suggesting
PUPCB is not cost-effective as a PU prevention strategy.
However, 29 (3.63%) participants in PUPCB and 7 (0.88%) in
standard care were defined as LOS outliers. When these outliers were
excluded, the difference in mean LOS reduced to 1.12 (95%CI 0.39 to
1.91) days and the difference in mean benefit associated with LOS re-
duced to $913 (95%CI $$320 to $1554) favouring standard care. After
removing outliers, the NMB for PUPCB compared to standard care is
−$1052.18 (95%CI −$1,697.35, −$437.70), which still favours
standard care. Thus, based on the cost-benefit analysis, PUPCB was
significantly more costly for significantly less benefit, than standard
care, suggesting the care bundle is not a cost-effective use of resources.
4. Discussion
This economic study presents to our knowledge one of only two
economic evaluations of a care bundle aimed at preventing one of the
most burdensome and avoidable adverse events associated with hos-
pital stay: pressure ulcer. The other evaluation was a literature-based
modelling study in Denmark (Mathiesen et al., 2013). The care bundle
presented in the current evaluation was patient-centred in nature, and
the evaluation was undertaken alongside a large pragmatic c-RT
enrolling nearly 1600 patients, making it unique. Whilst the c-RT was
equivocal (Chaboyer et al., 2016), it is possible for an intervention to be
shown to be cost-effective even if clinical efficacy is not demonstrated
(Briggs and O'Brien, 2001). However, this was not the case here. This
study was unable to provide consistent, conclusive evidence on the cost-
effectiveness of the PUPCB intervention for the prevention of HAPU,
possibly due to a lack of power resulting from the small cluster size of
the c-RT (8 hospital sites), along with the high variation observed in
costs, and the robustness of assumptions (e.g. whether to consider
length of stay as a potential benefit). Performing a study of sufficient
size and design to provide conclusive evidence is likely to require a
prohibitively large research budget.
The conclusion regarding cost-effectiveness of PUPCB in this study
is dependent on the method used for analysis, and in particular, on the
decision to include LOS costs in the cost-benefit estimate. The findings
of the cost-benefit analysis, which consider LOS as a potential benefit of
PUP, suggest PUPCB is not cost-effective in preventing PU, even after
excluding outliers. The finding of a higher LOS (and therefore negative
net benefit) in the PUPCB was unexpected and counter-intuitive to a
priori expectations in our study. It might be hypothesised a priori that
the PUPCB would be associated with lower rates of PU, and therefore
LOS and its associated costs would be lower in the PUPCB group. We
can only speculate why we found higher LOS in the PUPCB group.
However, we think this is unlikely to be directly associated with the
intervention. If we assume the difference in LOS benefits favouring
standard care is a random anomaly rather than a systematic finding,
then we might pay greater heed to the cost-effectiveness analysis which
does not consider LOS, rather than to the cost-benefit analysis. The
findings of the cost-effectivness analysis, which do not consider LOS
costs, suggest PUPCB is more likely than not to be cost-effective in
preventing PU at the assumed thresholds, but this is not conclusive as
there is a high level of uncertainty in the cost-effectiveness estimates.
In comparison to previous studies, the costs of prevention alone
suggested by this study (AU$98.90 for standard care and $242.91 for
PUPCB per patient) might be considered to be high. Demarre et al.,
undertook a systematic review of the cost of prevention or treatment of
PUs, and reported the cost of prevention to vary between Euro 2.65 to
87.57 (approximately AU$3.79 to $125.18 at 16 Nov16) per patient per
day, across all care settings (Demarre et al., 2015a). However, the
studies contributing data to this review were mostly based on secondary
data. It is possible that the data from our study which included a
comparatively large observational microcosting substudy is more ac-
curate. The previous Danish economic model concluded that labour
intensive efforts via a care bundle aimed at reducing PUs can be cost-
effective (Mathiesen et al., 2013). In fact contrary to our findings, their
Table 3
Difference in costs and outcomes (two-stage cluster-adjusted bootstrap).
PUPCB (per patient) Standard care (per patient) Difference per patient Mean (SE) [95% CI]
Costs (per patient)
Prevention costs 242.91 98.90 144.91 (44.09) [74.96, 246.08]
Outcomes (per patient)
Probability of avoiding a PU 0.93 0.89 0.04 (0.03) [−0.03, 0.12]
Days free of PU 6.35 5.23 1.12 (0.37) [0.34, 1.82]
Table 4
Cost-effectiveness of PUPCB compared to standard care.
Outcome ICER ($ per case prevented)
Mean (SE) [95%CI]
Additional case of PU prevented 3296 (621272) [–5068,144525]
Days PU prevented 151 (848) [57,313]
ICER Incremental cost-effectiveness ratio.
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model suggested that the care bundle was likely to be dominant (both
cost-saving and more effective at preventing PU than standard care). It
could be that the higher apparent costs in our study are driven by our
microcosting approach.
So what are the implications of the current study for a health au-
thority that might be considering implementing PUPCB in their tertiary
institution? While the main study provides no definitive answers, a
decision based solely on the criterion of cost-effectiveness from these
data and assuming the willingness to pay thresholds used in this study,
would be unlikely to adopt PUPCB into clinical practice. A decision-
maker might view the point estimates and considerable uncertainty as
unacceptable, and want further evidence before adoption. However, the
research costs associated with such a large trial are likely to be prohi-
bitive. Further evidence balancing research costs against the value of
implementing PUPCB could be gained by undertaking a value of in-
formation analysis (Claxton and Sculpher, 2006). However, this is a
technical approach; data would still be based on one trial only, and
undertaking such an approach would delay a decision.
Moreover, the implications of the findings are dependent on the
choice of analytic approach, with conclusions regarding cost-
effectiveness dependent on the choice of cost-effectiveness analysis or
cost-benefit analysis, and the associated decision whether to consider
benefits associated with LOS in the analysis. A less risk adverse deci-
sion-maker might take the perspective that the intervention is patient-
centred, reflects current international guidelines for PUP, might im-
prove clinical practice, offers a low risk of clinical harm and is com-
paratively low cost for the intervention itself. Any decision would be
context specific; however, if implemented, prospective data could be
collected to indicate HAPU rates before and after implementation as an
indicator of outcome and value for money.
Any conclusions regarding implementation of PUPCB should also
consider that several elements that might be relevant for a decision
were not included in the analysis. First, we used the PU stage observed
in the c-RT with short term follow up (maximum of 28 days) on which
to base our cost and benefit estimates. Once patients developed a PU
(which was a study endpoint), they exited the study and were not fol-
lowed up. While the main trial did not test the proposition that the
PUPCB decreases the likelihood of Stage I/II progressing to Stage III/IV
it is plausible that some of the Stage I and II HAPUs observed in the
clinical trial may be anticipated to progress to higher stage PUs with
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Fig. 1. Cost-effectiveness plane for PUPCB compared
to standard care.
Line indicates willingness to pay threshold of $3,786
per HAPU avoided. Points to the right of this line are
of acceptable cost-effectiveness at this threshold.
Fig. 2. Cost-effectiveness acceptability curve for PUPCB compared to
standard care.
The graph shows the probability PUPCB is cost-effective (y axis) for
each of a range of different willingess-to-pay thresholds per HAPU
avoided (x axis).
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time. The cost of managing a stage III or IV PU (A$17,442 or $22,467
respectively (Nguyen et al., 2015)) is substantially higher than stages I
or II. Moreover, to promote quality of care, some health authorities
implement fines for the occurrence of HAPU in their facilities. For ex-
ample in one Australian state, the Government fines facilities AU
$30,000 for each stage III and AU$50,000 for stage IV HAPU
(Queensland Health, 2012). US Medicaid does not reimburse hospitals
for PUs, and in the UK the safety thermometer is used and hospitals are
rewarded if their PUs lessen (Rosenthal, 2007; Power et al., 2012). As
the analysis in this evaluation was undertaken from a health system
perspective, this was not included in the estimate. Nevertheless, it
would likely be a consideration for the acceptability of implementing
PUPCB from an individual hospital perspective. Secondly, the higher
costs in the PUPCB arm were associated in part with the increased
nursing time required to turn patients and for skin inspection− which
are considered to be components of good nursing practice. These may
have benefits in addition to PUP such as providing an opportunity for
the nurse to engage with the patient, providing education, and re-
inforcing participation in PUP. Finally, given the follow-up of patients
was to hospital discharge or 28 days it was not feasible to record any
changes in HRQOL for patients in the trial and it was considered un-
likely to observe a HRQOL change in such a short time period. Never-
theless, any possible benefits in HRQOL have not been considered in the
assessment of cost-effectiveness.
Our interpretation of the findings of this study are also based on an
assumed willingness to pay threshold for PU prevention ($3786.43 per
PU prevented), which was equated to PU treatment costs reported in
the literature, from a health system perspective. The treatment cost
adopted from the literature was based on an Australian cost-of-illness
study by Nguyen et al. (Nguyen et al., 2015) which adopted selected
data from a UK study by Dealey et al. (Dealey et al., 2012) and included
direct health system costs (in hospital and in the community) to heal a
PU. These costs related to nursing time for risk assessment, monitoring
and repositioning, skin dressings, moisturiser, antibiotics, analgesics,
supporting surfaces, wound debridement, the management of compli-
cations in a small proportion (2.5 to 5%) of those with Stage II PU, and
for the indirect opportunity costs of any associated increase in length of
stay. Thus, the willingness to pay threshold used to interpret the study
is an estimate only, and takes no account of the value patients might
place on preventing a PU and its consequences, which could include
reduced quality of life, increased stay in hospital, negative impacts on
productivity, and informal care costs, particularly with higher stages of
PU. A more holistic value for PU prevention could be assessed directly
from patients and the public more widely using stated preference
methods such as discrete choice experiments or contingent valuation.
4.1. Limitations
As already indicated, the main limitation of this study is its in-
adequate power to give definitive guidance on cost-effectiveness,
driven by an inadequate sample size and/or cluster size, the compara-
tively small and unproven clinical benefit, the considerable patient
heterogeneity, and the short follow up. Sample size calculations were
not performed based on economic outcomes before conducting the
economic evaluation. The equivocal findings of this economic
evaluation highlight the need to consider the potential role of large
administrative datasets alongside trial data to estimate the costs and
benefits associated with interventions for the prevention of events such
as HAPU, where costs are highly variable and the highest cost events
(Stages II to IV) are comparatively rare. The current analysis also as-
sumed that resource use measured for the subsample on selected days
applied to the whole trial cohort across the time they were enrolled in
the study. However, measuring these resources for all patients was not
feasible for logistic reasons.
5. Conclusion
Overall, this study suggests a PUPCB consisting of multicomponent
nurse training and patient education strategies may encourage good
nursing practice but may not be cost-effective in preventing HAPU. If
PUPCB were to be implemented into practice in adult tertiary acute
care institutions, consideration should be given to collecting further
evidence alongside implementation to indicate real world costs and
outcomes, and to confirm any impact on LOS.
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